Hepatitis E virus in hematopoietic stem cell transplant recipients: A systematic review

Cruz, Sara; Campos, Carla Cristian; Timóteo, Mafalda; Tavares, Ana; Nascimento, María Säo José; Medeiros, Rui; Sousa, Hugo

doi:10.1016/j.jcv.2019.08.002

Cited by 6 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En los últimos años se ha descrito un mayor riesgo de hepatitis crónica debido a la infección por VHE en pacientes receptores de órganos sólidos, enfermedad que se presenta de curso rápido y grave, e incluso, con mortalidad por complicaciones hepáticas 68 . Los individuos que posteriormente a un trasplante de hígado adquieren la infección por el VHE, tienen un mayor riesgo de desarrollar una infección crónica; en estos se ha reportado una prevalencia de 7,4%, cifra que aumenta hasta 32,1% si el individuo es un receptor de trasplante de hígado con previa cirrosis hepática 69 ; también se ha reportado la frecuencia de anticuerpos contra VHE entre 2,5 y 16,3% en receptores de trasplante renal 70,71 , en receptores de trasplante de pulmón 3,2% y en receptores de trasplante de células hematopoyéticas 11,4% 72 .…”

Section: Infección Por Vhe En Receptores De Trasplantesunclassified

Virus de la hepatitis E

Sánchez-González

Rodríguez‐Perea

Bedoya

2022

Rev. chil. infectol.

View full text Add to dashboard Cite

El virus de la hepatitis E (VHE) es uno de los principales agentes etiológicos de hepatitis entérica en el mundo. En países en vía de desarrollo, la seroprevalencia oscila entre 20 y 50% y en países desarrollados entre 4,4 y 21%. Clínicamente los casos de infección por VHE en individuos inmunocompetentes cursan como una hepatitis viral aguda auto limitada; por el contrario, en mujeres embarazadas, individuos receptores de trasplantes de órganos e individuos que conviven con el virus de la inmunodeficiencia humana (VIH), la infección puede manifestarse como una hepatitis crónica y grave. En América Latina, sólo Brasil y Argentina reportan cifras en individuos que conviven con el VIH. Se requieren más estudios en nuestra región que permitan determinar la prevalencia del VHE en individuos inmunosuprimidos, donantes de sangre y población general para adoptar medidas que garanticen un diagnóstico oportuno, acceso a la atención y el control de la transmisión.Palabras clave: virus de la hepatitis E (VHE); virus de la inmunodeficiencia humana (VIH); seroprevalencia; inmunosupresión; hepatitis crónica.

show abstract

Section: Infección Por Vhe En Receptores De Trasplantesunclassified

Virus de la hepatitis E

Sánchez-González

Rodríguez‐Perea

Bedoya

2022

Rev. chil. infectol.

View full text Add to dashboard Cite

show abstract

“…Along with water-borne and food-borne transmission, transfusion-transmitted HEV (TT-HEV) infection has also been described [ 8 ]. The latter may be of a great concern for immunosuppressed patients, such as recipients of hematopoietic stem cell or solid organ transplants who are at risk of chronic HEV infection, resulting in persistent liver inflammation and cirrhosis [ 9 , 10 , 11 ]. The risk of TT-HEV infection is associated with HEV viremia in asymptomatic donors; the viremic period has recently been estimated to be up to 88 days [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis E Virus Infection in Voluntary Blood Donors in the Russian Federation

Potemkin,

Kyuregyan,

Karlsen

et al. 2024

Viruses

View full text Add to dashboard Cite

Transfusion-transmitted hepatitis E virus (HEV) infection is an increasing concern in many countries. We investigated the detection rate of HEV viremia in blood donors in Russia. A total of 20,405 regular repetitive voluntary non-renumerated blood donors from two regions (Moscow and Belgorod) were screened for HEV RNA using the cobas® HEV test in mini-pools of six plasma samples. Samples from each reactive pool were tested individually. The average HEV RNA prevalence was 0.024% (95% CI: 0.01–0.05%), or 1 case per 4081 donations. No statistically significant differences in HEV RNA prevalence were observed between the two study regions. The PCR threshold cycle (Ct) values ranged from 25.0 to 40.5 in reactive pools, and from 20.9 to 41.4 in reactive plasma samples when tested individually. The HEV viremic donors had different antibody patterns. Two donor samples were reactive for both anti-HEV IgM and IgG antibodies, one sample was reactive for anti-HEV IgM and negative for anti-HEV IgG, and two samples were seronegative. At follow-up testing 6 months later, on average, four donors available for follow-up had become negative for HEV RNA and positive for anti-HEV IgG. The HEV ORF2 sequence belonging to HEV-3 sub-genotype 3a was obtained from one donor sample. The sequencing failed in the other four samples from viremic donors, presumably due to the low viral load. In conclusion, the HEV RNA detection rate in blood donors in Russia corresponds with data from other European countries, including those that implemented universal donor HEV screening. These data support the implementation of HEV RNA donor screening to reduce the risk of transfusion-transmitted HEV infection in Russia.

show abstract

“…Sepsis‐associated liver injury (SALI) is also frequent and multifactorial 5 . Less often, relapse of haematological disease, cholelithiasis, viral reactivation (hepatitis B virus and cytomegalovirus), hepatitis E, 6 ischaemic hepatitis, iron overload (secondary in part to transfusions) 7 and metabolic dysfunction‐associated steatotic liver disease can also be the culprit 8 . More than 50% of the patients have liver function test (LFT) abnormalities and 25% have an increase of bilirubin after BMT 9 .…”

mentioning

confidence: 99%